Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Wall Street Analyst Weigh In

LGND has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 11th. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Benchmark reissued a “buy” rating and issued a $135.00 target price on shares of Ligand Pharmaceuticals in a report on Monday, December 23rd. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, Barclays increased their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $147.00.

Ligand Pharmaceuticals Trading Up 4.0 %

NASDAQ LGND traded up $4.61 during trading on Friday, reaching $120.28. 65,778 shares of the company’s stock were exchanged, compared to its average volume of 90,501. The company’s fifty day simple moving average is $114.03 and its 200-day simple moving average is $111.01. Ligand Pharmaceuticals has a fifty-two week low of $67.72 and a fifty-two week high of $129.90. The firm has a market capitalization of $2.27 billion, a PE ratio of 47.92 and a beta of 1.04.

Insider Activity at Ligand Pharmaceuticals

In related news, CFO Octavio Espinoza sold 2,104 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $116.37, for a total transaction of $244,842.48. Following the sale, the chief financial officer now directly owns 20,647 shares in the company, valued at $2,402,691.39. This trade represents a 9.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.